+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Immunotherapy"

From
From
Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
CAR-T Therapies Market (2nd Edition), 2019-2030 - Product Thumbnail Image

CAR-T Therapies Market (2nd Edition), 2019-2030

  • Report
  • August 2019
  • 580 Pages
  • Global
From
From
From
Loading Indicator

T Cell Immunotherapy is a type of immune disorder drug that works by harnessing the power of a patient's own immune system to fight disease. It involves the extraction of T cells from a patient's blood, which are then genetically modified to recognize and attack cancer cells. This modified T cell is then reintroduced into the patient's body, where it can recognize and destroy cancer cells. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. T Cell Immunotherapy has been shown to be effective in treating certain types of cancer, and is being studied for its potential to treat other types of cancer and immune disorders. It is also being studied for its potential to treat autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. Some companies in the T Cell Immunotherapy market include Novartis, Kite Pharma, Juno Therapeutics, and Celgene. Show Less Read more